Sign in

    Caroline Kimberly Pocher

    Research Analyst at JPMorgan Chase & Co.

    After conducting a thorough search, there is no publicly available evidence that Caroline Kimberly Pocher holds or has held an analyst position at JPMorgan Chase & Co., nor are there verifiable details regarding her job title, company coverage, professional credentials, career timeline, or performance metrics on major platforms. No professional profiles, such as on LinkedIn or industry sources, confirm her employment, sector specialization, or track record as a Wall Street analyst. Accordingly, no credible web profile or analyst summary can be provided at this time.

    Caroline Kimberly Pocher's questions to Seres Therapeutics (MCRB) leadership

    Caroline Kimberly Pocher's questions to Seres Therapeutics (MCRB) leadership • Q1 2025

    Question

    Caroline Kimberly Pocher, on behalf of Tessa Romero, inquired if partnership discussions for SER-155 are dependent on developmental milestones like protocol submission, and asked for details on the powering assumptions and adaptive design of the upcoming Phase 2 study.

    Answer

    President and CEO Eric Shaff clarified that securing a partnership is the primary gating item for initiating the SER-155 study, although progress is being made in parallel on operational readiness and FDA interactions. Regarding the study design, Eric Shaff and SVP of Clinical Development Dr. Dennis Walling explained that while specific powering statistics are not being shared, the Phase 2 study will be well-powered and its data could be part of a future submission. The adaptive design includes an interim analysis after about 12 months, intended to provide an early look at efficacy and facilitate earlier discussions with the FDA about a potential Phase 3 trial.

    Ask Fintool Equity Research AI

    Caroline Kimberly Pocher's questions to Seres Therapeutics (MCRB) leadership • Q4 2024

    Question

    Caroline Kimberly Pocher from JPMorgan Chase & Co., on behalf of Tessa Romero, asked how the recent FDA feedback on SER-155 aligned with the company's expectations, why the FDA recommended a Phase II study, and what the key differences would be between a standalone Phase II and a seamless Phase II/III trial design.

    Answer

    Eric Shaff, President and CEO, characterized the FDA feedback as constructive and robust, noting that the Breakthrough Therapy designation signals the agency's recognition of the high unmet need. Lisa von Moltke, CMO, elaborated that the primary difference with a seamless Phase II/III study is the requirement to prespecify and finalize more details upfront, which can take longer. She suggested the FDA's recommendation for more data is reasonable given the relatively small dataset from the initial Phase Ib study.

    Ask Fintool Equity Research AI

    Caroline Kimberly Pocher's questions to Seres Therapeutics (MCRB) leadership • Q3 2024

    Question

    Caroline Kimberly Pocher, on behalf of Tessa Romero, inquired about the profile of an ideal partner for SER-155, the targeted terms and timeline for a partnership, and the company's contingency plan if a deal does not materialize.

    Answer

    President and CEO Eric Shaff stated that an ideal partner would provide both capital and capabilities, such as global clinical trial expertise, to accelerate development. He emphasized the importance of aligned values and vision. While declining to provide a specific timeline, he confirmed Seres is proceeding with necessary study preparations. Shaff underscored that the company's primary focus is on securing a partnership and did not detail alternative steps.

    Ask Fintool Equity Research AI

    Caroline Kimberly Pocher's questions to Xenon Pharmaceuticals (XENE) leadership

    Caroline Kimberly Pocher's questions to Xenon Pharmaceuticals (XENE) leadership • Q4 2024

    Question

    Caroline Pocher of JPMorgan, on behalf of Tessa Romero, requested confirmation that enrollment in the X-TOLE2 study is not yet complete and asked for details on the Phase III trial design for bipolar depression, including patient population and endpoints.

    Answer

    President and CEO Ian Mortimer confirmed that the company has not yet commented on the completion of enrollment, reiterating the H2 2025 guidance for top-line data. He stated that specific details on the bipolar depression trial design will be disclosed closer to its initiation around mid-year. Chief Medical Officer Dr. Chris Kenney clarified that both planned bipolar studies will enroll a combination of patients with bipolar I and bipolar II disorders.

    Ask Fintool Equity Research AI